Neuroleptic Malignant Syndrome: Diagnosis and Management.
Ware MR, Feller DB, Hall KL.
Prim Care Companion CNS Disord. 2018 Jan 4;20(1):17r02185. doi: 10.4088/PCC.17r02185.
Neuroleptic malignant syndrome and serotonin syndrome.
Tormoehlen LM, Rusyniak DE.
Handb Clin Neurol. 2018;157:663-675. doi: 10.1016/B978-0-444-64074-1.00039-2.
Atypical Neuroleptic Malignant Syndrome: Case Reports and Diagnostic Challenges.
Szota AM, Radajewska I, Araszkiewicz AS.
J Psychoactive Drugs. 2022 Jul-Aug;54(3):284-293. doi: 10.1080/02791072.2021.1957188. Epub 2021 Aug 2.
[Neuroleptic malignant syndrome].
Reingardiene D.
Medicina (Kaunas). 2002;38(1):1-5.
Neuroleptic malignant syndrome: a review.
Pelonero AL, Levenson JL, Pandurangi AK.
Psychiatr Serv. 1998 Sep;49(9):1163-72. doi: 10.1176/ps.49.9.1163.
Neuroleptic malignant syndrome.
Bristow MF, Kohen D.
Br J Hosp Med. 1996 Apr 17-30;55(8):517-20.
Neuroleptic malignant syndrome.
Jahan MS, Farooque AI, Wahid Z.
J Natl Med Assoc. 1992 Nov;84(11):966-70.
Neuroleptic malignant syndrome.
Levenson JL.
Am J Psychiatry. 1985 Oct;142(10):1137-45. doi: 10.1176/ajp.142.10.1137.
Neuroleptic malignant syndrome.
Harrison PA, McErlane KS.
Am J Nurs. 2008 Jul;108(7):35-8. doi: 10.1097/01.NAJ.0000325810.75594.cb.
Neuroleptic malignant syndrome.
Abbott RJ, Loizou LA.
Br J Psychiatry. 1986 Jan;148:47-51. doi: 10.1192/bjp.148.1.47.
